JP2022548043A5 - - Google Patents
Info
- Publication number
- JP2022548043A5 JP2022548043A5 JP2022516107A JP2022516107A JP2022548043A5 JP 2022548043 A5 JP2022548043 A5 JP 2022548043A5 JP 2022516107 A JP2022516107 A JP 2022516107A JP 2022516107 A JP2022516107 A JP 2022516107A JP 2022548043 A5 JP2022548043 A5 JP 2022548043A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- acid sequence
- seq
- antibody
- polypeptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025064114A JP2025118629A (ja) | 2019-09-13 | 2025-04-09 | 抗腫瘍溶解性ウイルス抗原抗体およびその使用方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962900303P | 2019-09-13 | 2019-09-13 | |
| US62/900,303 | 2019-09-13 | ||
| PCT/CA2020/051230 WO2021046653A1 (en) | 2019-09-13 | 2020-09-11 | Anti-oncolytic virus antigen antibodies and methods of using same |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025064114A Division JP2025118629A (ja) | 2019-09-13 | 2025-04-09 | 抗腫瘍溶解性ウイルス抗原抗体およびその使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022548043A JP2022548043A (ja) | 2022-11-16 |
| JP2022548043A5 true JP2022548043A5 (https=) | 2023-09-15 |
| JP7665600B2 JP7665600B2 (ja) | 2025-04-21 |
Family
ID=74867304
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022516107A Active JP7665600B2 (ja) | 2019-09-13 | 2020-09-11 | 抗腫瘍溶解性ウイルス抗原抗体およびその使用方法 |
| JP2025064114A Pending JP2025118629A (ja) | 2019-09-13 | 2025-04-09 | 抗腫瘍溶解性ウイルス抗原抗体およびその使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025064114A Pending JP2025118629A (ja) | 2019-09-13 | 2025-04-09 | 抗腫瘍溶解性ウイルス抗原抗体およびその使用方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20230027475A1 (https=) |
| EP (1) | EP4028417A4 (https=) |
| JP (2) | JP7665600B2 (https=) |
| KR (1) | KR20220093103A (https=) |
| CN (2) | CN118834291A (https=) |
| AU (1) | AU2020346632A1 (https=) |
| BR (1) | BR112022004575A2 (https=) |
| CA (1) | CA3154214A1 (https=) |
| MX (1) | MX2022002855A (https=) |
| WO (1) | WO2021046653A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7456584B2 (ja) * | 2019-10-02 | 2024-03-27 | バイオノックス インコーポレイテッド | 腫瘍標的化タンパク質又はその断片、それに結合する抗体及びその使用 |
| US20240309070A1 (en) * | 2021-03-17 | 2024-09-19 | adMare Therapeutics Society | Anti-vaccinia virus antigen antibodies and related compositions and methods |
| KR102419397B1 (ko) * | 2021-04-02 | 2022-07-14 | 주식회사 바이오녹스 | 항암바이러스 유래 단백질을 표적으로 하는 키메라 항원 수용체, 이를 발현하는 면역세포 및 이들의 용도 |
| KR102739298B1 (ko) * | 2021-04-02 | 2024-12-06 | 주식회사 바이오녹스 | 바이러스 벡터 유래 항암요법 표적 단백질 및 이에 특이적으로 결합하는 결합 분자 또는 이의 단편 |
| JP7842773B2 (ja) * | 2021-04-05 | 2026-04-08 | バイオノックス インコーポレイテッド | 抗癌治療のためのウイルスベクター由来標的タンパク質及びそれと特異的に結合する結合分子又はその断片 |
| CN117480245A (zh) * | 2021-04-05 | 2024-01-30 | 拜耳诺克斯有限公司 | 靶向源自溶瘤病毒的蛋白的嵌合抗原受体、表达其的免疫细胞及两者的用途 |
| KR102759386B1 (ko) * | 2022-08-11 | 2025-01-24 | 성균관대학교산학협력단 | 89Zr 표지된 항-CD25 항체를 이용한 immuno-PET |
| KR102770091B1 (ko) * | 2023-04-03 | 2025-02-24 | 주식회사 셀랩메드 | 종양 용해성 바이러스 단백질-특이적 키메릭 항원 수용체 및 이의 용도 |
| WO2024210531A1 (ko) * | 2023-04-03 | 2024-10-10 | 주식회사 셀랩메드 | 종양 용해성 바이러스 단백질-특이적 키메릭 항원 수용체 및 이의 용도 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007075914A2 (en) * | 2005-12-22 | 2007-07-05 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Monoclonal antibodies against orthopoxviruses |
| CN101553255A (zh) * | 2006-08-23 | 2009-10-07 | 奎尔斯根制药有限责任公司 | 天花单克隆抗体 |
| WO2009048769A2 (en) * | 2007-10-10 | 2009-04-16 | Kirin Pharma Kabushiki Kaisha | Vaccinia virus h3l and b5r specific monoclonal antibodies and methods of making and using same |
| KR101581244B1 (ko) * | 2008-03-26 | 2015-12-31 | 에피토믹스, 인코포레이티드 | 항―ｖｅｇｆ 항체 |
| BR112018012180A2 (pt) * | 2015-12-17 | 2018-12-04 | Psioxus Therapeutics Ltd | vírus de codificação de um anticorpo ou fragmento de complexo anti-tcr |
| AR107078A1 (es) * | 2015-12-18 | 2018-03-21 | Chugai Pharmaceutical Co Ltd | Anticuerpo antimiostatina, polipéptidos que contienen regiones fc variantes así como métodos de uso |
| WO2018064602A1 (en) * | 2016-09-30 | 2018-04-05 | Baylor College Of Medicine | Chimeric antigen receptor therapy with reduced cytotoxicity for viral disease |
| WO2019028051A1 (en) * | 2017-07-31 | 2019-02-07 | Lentigen Technology, Inc. | COMPOSITIONS AND METHODS FOR TREATING CANCER BY ANTI-CD19 / CD20 IMMUNOTHERAPY |
| WO2019033030A1 (en) * | 2017-08-11 | 2019-02-14 | City Of Hope | ONCOLYTIC VIRUS EXPRESSING A CAR-T CELL TARGET AND USES THEREOF |
| US20240309070A1 (en) * | 2021-03-17 | 2024-09-19 | adMare Therapeutics Society | Anti-vaccinia virus antigen antibodies and related compositions and methods |
-
2020
- 2020-09-11 CA CA3154214A patent/CA3154214A1/en active Pending
- 2020-09-11 EP EP20863181.2A patent/EP4028417A4/en active Pending
- 2020-09-11 CN CN202410848156.9A patent/CN118834291A/zh active Pending
- 2020-09-11 CN CN202080079310.0A patent/CN114729031B/zh active Active
- 2020-09-11 MX MX2022002855A patent/MX2022002855A/es unknown
- 2020-09-11 BR BR112022004575A patent/BR112022004575A2/pt unknown
- 2020-09-11 US US17/642,089 patent/US20230027475A1/en active Pending
- 2020-09-11 KR KR1020227012100A patent/KR20220093103A/ko active Pending
- 2020-09-11 WO PCT/CA2020/051230 patent/WO2021046653A1/en not_active Ceased
- 2020-09-11 AU AU2020346632A patent/AU2020346632A1/en active Pending
- 2020-09-11 JP JP2022516107A patent/JP7665600B2/ja active Active
-
2025
- 2025-04-09 JP JP2025064114A patent/JP2025118629A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022548043A5 (https=) | ||
| JP7199494B2 (ja) | Ｃｄ４７に対するヒト化及びキメラモノクローナル抗体 | |
| US10781256B2 (en) | Anti SIRP-α antibodies and bi-specific macrophage enhancing antibodies | |
| TWI743461B (zh) | 具有交叉結合區定向之雙重可變區類抗體結合蛋白 | |
| JP2021528973A5 (https=) | ||
| JP2022523507A5 (https=) | ||
| CN106659779A (zh) | 双特异性四价抗体及其制造和使用方法 | |
| WO2020252907A1 (zh) | 抗cd3e和bcma双特异性抗体及其用途 | |
| JP2020533004A5 (https=) | ||
| JP2023524102A5 (https=) | ||
| JP2022513050A5 (https=) | ||
| CN114786720B (zh) | TriAx抗体的组合物及其制备和使用方法 | |
| JP2025506341A5 (https=) | ||
| US20230406929A1 (en) | Polypeptide constructs binding to cd3 | |
| US20230406887A1 (en) | Antigen binding domain with reduced clipping rate | |
| CN118754989B (zh) | 一种抗her2纳米抗体及其制备方法和应用 | |
| JP2024513700A5 (https=) | ||
| CN120981244A (zh) | Vhh抗体和其用途 | |
| WO2023143273A1 (zh) | 新型长效化和高活性且更安全的抗体构建体 | |
| JP2023548471A5 (https=) | ||
| CN105229034B (zh) | 用于与抗体药物偶联物疗法一起使用的免疫成像剂 | |
| JP2023536630A5 (https=) | ||
| JP2022517329A5 (https=) | ||
| JP2025512923A5 (https=) | ||
| CN105143272A (zh) | 用于与抗体药物偶联物疗法一起使用的免疫成像剂 |